Merck Finalizes Mirus Bio Acquisition, Enhancing Its Viral Vector Bioprocessing Offerings
Friday, August 02, 2024
Merck, a prominent science and technology firm, has finalized its acquisition of Mirus Bio for approximately $600 million (€550 million). This transaction, which concluded after securing regulatory approvals and satisfying other standard closing requirements, represents a key strategic initiative for Merck. The acquisition supports Merck’s objective of delivering end-to-end solutions for viral vector production and reinforces its dedication to progressing cell and gene therapies from preclinical stages to commercial production. Mirus Bio was acquired from Gamma Biosciences, a life sciences platform backed by global investment firm KKR.
Sebastian Arana, Head of Process Solutions in Merck’s Life Science division, remarked, “Emerging treatments such as cell and gene therapies offer significant promise for new, curative options for patients. By integrating Mirus Bio’s cutting-edge technology with our bioprocessing capabilities and comprehensive portfolio, we are positioned to offer seamless solutions across the viral vector manufacturing spectrum and meet the increasing demand for these critical therapies.”
Mirus Bio specializes in transfection reagents, including TransIT-VirusGEN®, which are essential for producing viral vector-based gene therapies. The acquisition will enhance Merck’s upstream offerings and provide a more cohesive approach to viral vector manufacturing.
This deal further strengthens Merck’s extensive portfolio in the Life Science sector, which supports every stage of viral vector production from early development to commercial output. Merck’s range includes cell lines, culture media, process materials (like chemicals, buffers, and enzymes), as well as systems, filters, hardware, and consumables. The company’s expertise covers various viral vector types, such as adeno-associated virus, lentivirus, and adenovirus, and it offers contract testing and comprehensive CDMO services, benefiting from three decades of experience in the field.
Source: merckgroup.com
